A federal advisory panel approved the use of the Pfizer vaccine on younger adolescents aged 12 to 15 years old on May 12.
The Advisory Committee …
A federal advisory panel approved the use of the Pfizer vaccine on younger adolescents aged 12 to 15 years old on May 12. The Advisory Committee on Immunization Practices, which offers assistance to the U.S. Centers for Disease Control and Prevention (CDC), voted unanimously 14-0 in favor of the vaccine, saying that after evaluating trial evidence, it showed no cases of severe allergic reactions or Bell’s Palsy on the age group, and that none of them contracted COVID-19. “This will provide protection for 12 to 15-year-olds,” Dr. Henry Bernstein, a member of the advisory committee and professor of pediatrics at Zucker School of Medicine at Hofstra/Northwell, said. On Monday, the FDA approved the usage expansion for the Pfizer vaccine. Pfizer’s testing in adolescents “met our rigorous standards,” FDA vaccine chief Dr.
